HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy.
about
Immunovirological parameters and cytokines in HIV infectionIncomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutionsResidual viremia in an RT-SHIV rhesus macaque HAART model marked by the presence of a predominant plasma clone and a lack of viral evolutionAssociation of low level viremia with inflammation and mortality in HIV-infected adultsCharacterizing Patients with Very-Low-Level HIV Viremia: A Community-Based StudyAssociation between latent proviral characteristics and immune activation in antiretrovirus-treated human immunodeficiency virus type 1-infected adultsEvidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals.HIV-1 low-level viraemia assessed with 3 commercial real-time PCR assays show high variability.Immune activation and HIV persistence: implications for curative approaches to HIV infection.A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response.Immune activation in HIV-infected aging women on antiretrovirals--implications for age-associated comorbidities: a cross-sectional pilot study.Persistent immune activation in chronic HIV infection: do any interventions work?Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study.Metabolic and anthropometric parameters contribute to ART-mediated CD4+ T cell recovery in HIV-1-infected individuals: an observational studyAltered CD4+ T cell homing to the gut impairs mucosal immune reconstitution in treated HIV-infected individuals.HIV Replication at Low Copy Number and its Correlation with the HIV Reservoir: A Clinical Perspective.High Current CD4+ T Cell Count Predicts Suboptimal Adherence to Antiretroviral Therapy.Interleukin-37 Expression Is Increased in Chronic HIV-1-Infected Individuals and Is Associated with Inflammation and the Size of the Total Viral ReservoirDiscordant Immune Response with Antiretroviral Therapy in HIV-1: A Systematic Review of Clinical Outcomes.Interleukin 10 responses are associated with sustained CD4 T-cell counts in treated HIV infectionAntiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activationThe role of cytokines in the establishment, persistence and eradication of the HIV reservoirModification of the Abbott RealTime assay for detection of HIV-1 plasma RNA viral loads less than one copy per milliliter.Serious Non-AIDS events: Immunopathogenesis and interventional strategies.Stimulation of PBMC and Monocyte-Derived Macrophages via Toll-Like Receptor Activates Innate Immune Pathways in HIV-Infected Patients on Virally Suppressive Combination Antiretroviral TherapyFactors Associated with the Size of HIV DNA Reservoir.Persistent Cryptococcal Brain Infection despite Prolonged Immunorecovery in an HIV-Positive Patient.HIV reservoirs and strategies for eradication.Immunodiscordant responses to HAART--mechanisms and consequences.Evaluation of the pharmacogenetics of immune recovery in treated HIV-infected patients.Potential implication of residual viremia in patients on effective antiretroviral therapy.Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia.Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV InfectionDiscordance between peripheral and colonic markers of inflammation during suppressive ARTFactors associated with a strictly undetectable viral load in HIV-1-infected patients.Time course of cellular HIV-DNA and low-level HIV viremia in HIV-HCV co-infected patients whose HCV infection had been successfully treated with directly acting antivirals.Evaluation of HIV-DNA and inflammatory markers in HIV-infected individuals with different viral load patterns.Brief Report: A High Rate of β7+ Gut-Homing Lymphocytes in HIV-Infected Immunological Nonresponders is Associated With Poor CD4 T-Cell Recovery During Suppressive HAARTCCR6(-) regulatory T cells blunt the restoration of gut Th17 cells along the CCR6-CCL20 axis in treated HIV-1-infected individuals.Determinants of residual viraemia during combination HIV treatment: Impacts of baseline HIV RNA levels and treatment choice.
P2860
Q26829264-4C3D0AAF-E6E8-4DCC-A925-42E3F564938EQ27021524-D0A2A9CA-C5D8-4D5B-87AF-38E18C5DD750Q28539563-4082121D-A852-47F5-91C4-49478EC83B4EQ28743237-62040450-C5FF-4BCA-BC2B-2E2C1C5B7F95Q33653518-24D7BB9D-5C79-453E-8D18-643F36841F94Q34057868-7B67968F-8206-4990-AEB4-72D441C0F5D3Q34195386-70B2654B-DB1C-48FD-8623-9D5557E905EDQ34244228-EDAE3AAF-94F2-4DA3-9A4F-0468728251E1Q34351320-33EBB645-AB72-4466-9C15-1CFEBE3D838CQ34743336-B69E912C-1E33-4AC2-B1F4-3698A0460BBEQ34749335-0F6A02E4-74EF-4C1D-8BA6-39644FE8BD7CQ34851102-2EA1B784-3287-4EC7-8A59-C3C36387CA63Q35109483-70900334-AC34-4CF6-8107-EAF6A8E5B1E0Q35185674-3C66F5D3-38F9-4EB5-90C9-39E656A7AC1CQ35640599-31F09234-C49B-4665-A980-FD33A9F03645Q35698144-BD0EA34D-3F7E-4795-829D-F112D002C4B4Q35808100-038F0E9F-F63A-4624-8300-B2CD4860251EQ35946786-43E4278B-58C9-44D9-8DA0-1B66CAA0D4D0Q36047903-4D2A4B4C-11F2-4234-8414-F6F0ABF316D8Q36379299-F857AE6B-2F9C-4E2B-A122-7AAA30F92BB4Q36930492-0B7B900A-79D2-4166-B1A1-0A1647C1243AQ37157209-932AF63A-663D-4F80-B44B-E224D9B6CD4EQ37308125-D4F4F162-188A-467C-8592-02A78FF509F4Q37418140-B07158E1-81F1-41CC-8CB8-B0D36CC35077Q37513027-7B5EACA7-DF21-4FA0-80A0-B3DC5E29C1B7Q37615584-7B6CEB39-BFE2-41EF-906B-2DF6601444D3Q37673623-2516BDAF-21A0-4744-8AAC-24EE4E9247F3Q37976293-3E75CD16-A30F-4B5C-B79E-6BF5A874881CQ38156230-9464D6D1-9789-450E-BEBD-338EED63345EQ38164430-D92DE949-0F91-4955-B3DC-C28FF4D34BF9Q38271917-E4BBA265-40F5-4C6B-8D23-C27766C2637DQ38411418-671E978A-D02F-4B6E-B47E-E28CC9DD79A6Q38749963-B26D1980-64D7-4F36-985C-48A9078FC3BDQ38930864-214626EA-C1A7-483D-AFAA-5367F8DEB92AQ39219128-55F9E1BD-DF23-4C86-81D2-39FB212C4DFEQ40060728-BF3478A4-E2F6-46AA-BA00-EF052884BD1EQ40075058-F65D753F-DA4D-4910-BE6A-E369B768307DQ40699445-A3437910-09D4-4B9A-8967-6C1F439C7E88Q40789003-6F842E56-F850-46F1-A79B-353837B8E64EQ40922638-040EE866-B79F-45FF-96F7-5E54FB15D202
P2860
HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy.
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
HIV-1 residual viremia correla ...... nation antiretroviral therapy.
@ast
HIV-1 residual viremia correla ...... nation antiretroviral therapy.
@en
HIV-1 residual viremia correla ...... nation antiretroviral therapy.
@nl
type
label
HIV-1 residual viremia correla ...... nation antiretroviral therapy.
@ast
HIV-1 residual viremia correla ...... nation antiretroviral therapy.
@en
HIV-1 residual viremia correla ...... nation antiretroviral therapy.
@nl
prefLabel
HIV-1 residual viremia correla ...... nation antiretroviral therapy.
@ast
HIV-1 residual viremia correla ...... nation antiretroviral therapy.
@en
HIV-1 residual viremia correla ...... nation antiretroviral therapy.
@nl
P2093
P2860
P50
P1433
P1476
HIV-1 residual viremia correla ...... ination antiretroviral therapy
@en
P2093
Bruno Marchou
Fatima-Ezzahra L'faqihi-Olive
Jacques Izopet
Martine Dubois
Maud Mavigner
Michelle Cazabat
Patrice Massip
P2860
P356
10.1371/JOURNAL.PONE.0007658
P407
P577
2009-10-30T00:00:00Z